Equities

ImmuCell Corp

ImmuCell Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.63
  • Today's Change0.03 / 0.83%
  • Shares traded21.30k
  • 1 Year change-31.38%
  • Beta0.5656
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects ImmuCell Corp share price to rise to 14.00 in the next year from the last price of 3.63.
High285.7%14.00
Med285.7%14.00
Low285.7%14.00

Earnings history & estimates in USD

On Feb 22, 2021, ImmuCell Corp reported 4th quarter 2020 earnings of 0.03 per share.
Average growth rate+63.64%
ImmuCell Corp reported annual 2020 losses of -0.14 per share on Feb 22, 2021.
More ▼

Revenue history & estimates in USD

ImmuCell Corporation had 4th quarter 2020 revenues of 3.74m. This missed the 4.00m estimate of the one analyst following the company. The same period last year the company did not report revenues.
Average growth rate+13.03%
ImmuCell Corporation had revenues for the full year 2020 of 15.34m. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.